12:00 AM
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NicVax: Phase III started

Nabi began a double-blind, placebo-controlled Phase III trial to evaluate NicVax in about 1,000 patients. The company has an SPA from FDA...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >